Skip to main content
Alteogen Inc. logo

Alteogen Inc. — Investor Relations & Filings

Ticker · 196170 ISIN · KR7196170005 KO Professional, scientific and technical activities
Open in API
Filings indexed 293 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 196170

About Alteogen Inc.

http://www.alteogen.com/

Alteogen Inc. is a biopharmaceutical company focused on the development and commercialization of next-generation biologics. The company's core activities are centered on its proprietary platform technologies. These include Hybrozyme™, a novel recombinant human hyaluronidase (ALT-B4) technology that enables the conversion of intravenous (IV) therapies to subcutaneous (SC) formulations, enhancing patient convenience. Additionally, Alteogen develops long-acting biobetters utilizing its NexP™ fusion technology, proprietary antibody-drug conjugates (ADCs), and antibody biosimilars. The company's pipeline is aimed at creating therapies with enhanced efficacy and delivery methods for serious diseases.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 94% confidence The document is titled '분기보고서' (Korean for 'Quarterly Report') covering the period 2026-01-01 to 2026-03-31 and contains detailed financial data, tables on capital changes, stock breakdowns, company overview, history, and other substantive interim-period disclosures. It is not merely an announcement or link to a report but the full interim financial report itself. Therefore it matches the 'Interim / Quarterly Report' category. Q1 2026
2026-05-15 Korean
투자판단관련주요경영사항 (아이젠피주(ALT-L9, 아일리아 바이오시밀러) 식약처 품목허가 승인)
Regulatory Filings Classification · 82% confidence The document is an announcement of a significant corporate event (MFDS approval of a new product) relating to investment decisions. It does not contain financial statements, management or board changes, dividends, earnings, or other specific categories. It is a general regulatory announcement, fitting the fallback category ‘Regulatory Filings’ (RNS).
2026-05-15 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Regulatory Filings
2026-05-08 Korean
주식등의대량보유상황보고서(일반)
Regulatory Filings
2026-04-07 Korean
기업설명회(IR)개최
Investor Presentation Classification · 85% confidence The document is an announcement of a scheduled investor relations meeting (‘기업설명회(IR) 개최’) with date, time, venue, target audience, purpose, agenda, and link to where IR materials will be posted. This aligns with an Investor Presentation (IP) category, which covers presentations arranged for investors focusing on company overview and strategy.
2026-04-07 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 90% confidence The document is a formal notification to the Financial Supervisory Service and Korea Exchange regarding the appointment, dismissal, or early retirement of outside directors (사외이사 선임·해임). It details changes in board composition and director term information. This matches the Board/Management Information category (MANG).
2026-04-01 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.